When you get sick, your immune system produces antibodies. Billions of tests are performed each year to detect these molecules as an indicator of disease. Enable Biosciences’ approach could help diagnose diseases like HIV and type 1 diabetes at an earlier, more easily treatable stage.
Our platform uses DNA tags in a completely solution-phase immunoassay. This preserves the native antigen for detecting conformationally sensitive epitopes, like those often seen in autoantibody biomarkers.
Enable’s technology platform was developed by scientists at Stanford and UC Berkeley. The team won the 2016 Stanford Predictive and Diagnostics Accelerator prize and the 2016 Harvard Business School New Ventures Competition (HBS NVC) for Northern California. We were a top 4 finisher at the global HBS NVC finals.